← All trials
NCT04982068
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Oct 31, 2022
- First posted
- Jul 29, 2021
- Last posted
- Aug 3, 2021
- Enrollment
- 144
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Zerun Biotechnology Co.,LtdLead sponsor
- Walvax Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.